{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neurogenic+Detrusor+Overactivity",
    "query": {
      "condition": "Neurogenic Detrusor Overactivity"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 24,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neurogenic+Detrusor+Overactivity&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-21T22:54:45.539Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05491525",
      "title": "A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Neurogenic Detrusor Overactivity"
      ],
      "interventions": [
        {
          "name": "Vibegron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Urovant Sciences GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 85,
      "start_date": "2022-10-12",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2024-07-03",
      "last_synced_at": "2026-05-21T22:54:45.539Z",
      "location_count": 6,
      "location_summary": "Orange, California • Jacksonville, Florida • Wichita, Kansas + 3 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Albany",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05491525"
    },
    {
      "nct_id": "NCT05141487",
      "title": "Feasibility of Triggered Sacral Neuromodulation for Neurogenic Bladder",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Urinary Incontinence",
        "Urinary Bladder, Neurogenic"
      ],
      "interventions": [
        {
          "name": "UroMonitor",
          "type": "DEVICE"
        },
        {
          "name": "ASCU",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2022-10-03",
      "completion_date": "2026-10-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-15",
      "last_synced_at": "2026-05-21T22:54:45.539Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05141487"
    },
    {
      "nct_id": "NCT00583219",
      "title": "Botulin-A Toxin Instillations and Overactive Bladder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Overactive Bladder",
        "Detrusor Instability",
        "Detrusor Hyperreflexia"
      ],
      "interventions": [
        {
          "name": "Botulinum-A toxin",
          "type": "DRUG"
        },
        {
          "name": "Dimethyl sulfoxide (DMSO)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 25,
      "start_date": "2006-03",
      "completion_date": "2008-05",
      "has_results": true,
      "last_update_posted_date": "2014-04-21",
      "last_synced_at": "2026-05-21T22:54:45.539Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00583219"
    },
    {
      "nct_id": "NCT01600716",
      "title": "Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Urinary Incontinence",
        "Multiple Sclerosis",
        "Neurogenic Bladder"
      ],
      "interventions": [
        {
          "name": "OnabotulinumtoxinA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Normal Saline)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 144,
      "start_date": "2012-06-13",
      "completion_date": "2015-03-27",
      "has_results": true,
      "last_update_posted_date": "2019-04-30",
      "last_synced_at": "2026-05-21T22:54:45.539Z",
      "location_count": 1,
      "location_summary": "Mountlake Terrace, Washington",
      "locations": [
        {
          "city": "Mountlake Terrace",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01600716"
    },
    {
      "nct_id": "NCT03033355",
      "title": "Central Nervous System Changes Following OnabotulinumtoxinA Injection in the Bladder",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis",
        "Lower Urinary Tract Symptoms",
        "Neurogenic Bladder",
        "Detrusor, Overactive",
        "Urge Incontinence"
      ],
      "interventions": [
        {
          "name": "Intra-detrusor injection of Onabotulinumtoxin-A",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Methodist Hospital Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 12,
      "start_date": "2014-02",
      "completion_date": "2019-03",
      "has_results": true,
      "last_update_posted_date": "2025-08-05",
      "last_synced_at": "2026-05-21T22:54:45.539Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03033355"
    },
    {
      "nct_id": "NCT01981954",
      "title": "A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neurogenic Detrusor Overactivity",
        "Pediatric"
      ],
      "interventions": [
        {
          "name": "Solifenacin succinate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Europe B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "4 Years",
        "sex": "ALL",
        "summary": "6 Months to 4 Years"
      },
      "enrollment_count": 23,
      "start_date": "2013-09-25",
      "completion_date": "2015-12-18",
      "has_results": true,
      "last_update_posted_date": "2024-10-31",
      "last_synced_at": "2026-05-21T22:54:45.539Z",
      "location_count": 1,
      "location_summary": "Tarrytown, New York",
      "locations": [
        {
          "city": "Tarrytown",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01981954"
    },
    {
      "nct_id": "NCT00667095",
      "title": "Over Active Bladder Instillation Study - Botox",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Overactive Bladder",
        "Urinary Urge Incontinence",
        "Urinary Incontinence",
        "Detrusor Hyperreflexia",
        "Urge Incontinence"
      ],
      "interventions": [
        {
          "name": "Botox Instillation",
          "type": "DRUG"
        },
        {
          "name": "DMSO Instillation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 25,
      "start_date": "2008-04",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2014-07-11",
      "last_synced_at": "2026-05-21T22:54:45.539Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00667095"
    },
    {
      "nct_id": "NCT01852058",
      "title": "A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Urinary Incontinence"
      ],
      "interventions": [
        {
          "name": "OnabotulinumtoxinA",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 95,
      "start_date": "2014-01-11",
      "completion_date": "2019-10-03",
      "has_results": true,
      "last_update_posted_date": "2020-05-12",
      "last_synced_at": "2026-05-21T22:54:45.539Z",
      "location_count": 14,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01852058"
    },
    {
      "nct_id": "NCT01050114",
      "title": "OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "onaBoNT-A",
          "type": "DRUG"
        },
        {
          "name": "Oxybutynin ER",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Christopher Patrick Smith",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 36,
      "start_date": "2013-08",
      "completion_date": "2018-07",
      "has_results": false,
      "last_update_posted_date": "2016-08-30",
      "last_synced_at": "2026-05-21T22:54:45.539Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01050114"
    },
    {
      "nct_id": "NCT00712322",
      "title": "A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neurogenic Detrusor Overactivity"
      ],
      "interventions": [
        {
          "name": "Darifenacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Warner Chilcott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "15 Years",
        "sex": "ALL",
        "summary": "2 Years to 15 Years"
      },
      "enrollment_count": 35,
      "start_date": "2008-10-07",
      "completion_date": "2013-05-23",
      "has_results": true,
      "last_update_posted_date": "2022-06-09",
      "last_synced_at": "2026-05-21T22:54:45.539Z",
      "location_count": 9,
      "location_summary": "San Diego, California • Boston, Massachusetts • Detroit, Michigan + 6 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Lake Success",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00712322"
    }
  ]
}